EUCTR2019-002745-38-GB进行中（未招募）1 期
An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 when Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, NonMetastatic Head and Neck Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Pathologically-confirmed diagnosis of locally advanced squamous cell carcinoma of the head and neck that will be treated with cisplatin plus concurrent IMRT.
- •Note: Patients with unknown primary tumors whose treatment plan matches the requirements specified in Inclusion Criteria #2 and #3 below are eligible for the study.
- •2. Treatment plan to receive a continuous course of IMRT delivered as single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose of 60-72 Gy. Planned radiation fields must include at least 2 oral sites (left and right buccal mucosa, floor of mouth, left and right lateral tongue, soft palate) with each site receiving a cumulative dose of at least 50 Gy.
- •Note: Unavoidable doses of at least 50 Gy, to include entrance, exit, and scatter doses, still constitute planned radiation.
- •3. Patients who have had prior surgery are eligible, provided they have fully recovered from surgery, and patients who may have surgery in the future are eligible.
- •4. Treatment plan to receive standard cisplatin monotherapy administered either every three weeks (100 mg/m2 for 3 doses) or weekly (40 mg/m2 for 6-7 doses). The decision on which cisplatin regimen to use in combination with IMRT and GC4419 will be at the discretion of the Investigator.
- •5. Age 18 years or older
- •6. Eastern Cooperative Oncology Group (ECOG) performance status = 2
- •7. Adequate hematologic function as indicated by:
- •- Absolute neutrophil counts (ANC) = 1,500/mm3
- •- Hemoglobin (Hgb) = 9.0 g/dL
- •- Platelet count = 100,000/mm3
- •8. Adequate renal and liver function as indicated by:
- •- Serum creatinine acceptable for treatment with cisplatin per institutional guidelines
- •- Total bilirubin = 1.5 x upper-normal limit (ULN)
- •- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN
- •- Alkaline phosphatase = 2.5 x ULN
- •9. Serum pregnancy test negative for women of childbearing potential
- •10. Males and females must agree to use highly effective method of contraception starting prior to the first day of treatment and continuing after the last dose of GC4419 for 30 days (females) or 90 days (males)
- •11. Properly obtained written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Metastatic disease
- •2. Prior radiotherapy to the region of the study cancer or adjacent anatomical sites or more than 25% of total body marrow-bearing area (potentially interfering with chemo-tolerance)
- •3. Prior induction chemotherapy or plans for chemotherapy to be administered only sequentially, not concurrently, with IMRT
- •4. Planned concurrent chemotherapy other than single agent cisplatin
- •5. Receiving any approved or investigational anti-cancer agent other than those provided for in this study
- •6. Concurrent participation in another interventional clinical study or use of another investigational agent within 30 days of first dose of GC4419
- •Note: Patients who are participating in non-interventional clinical studies (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.
- •7. Inability to eat soft solid food at baseline for reasons other than mouth soreness after surgery or dental procedures
- •8. Complete reliance on parenteral or gastrointestinal tube-delivered nutrition at baseline
- •Note: Patients who have gastrostomy tubes prophylactically placed are eligible. Patients receiving supplemental nutrition through a gastrostomy tube at baseline may be eligible depending on diet.
- •9. Malignant tumors other than head and neck cancer (HNC) within the last 5 years, unless treated definitively and with low risk of recurrence in the judgment of the treating Investigator
- •10. Active infectious disease excluding oral candidiasis
- •11. Presence of oral mucositis at baseline. Subjects with mouth or throat pain solely due to postoperative effects are eligible, however.
- •12. Known history of human immunodeficiency virus (HIV) or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)
- •13. Female patients who are pregnant or breastfeeding
- •14. Known allergies or intolerance to cisplatin and similar platinum-containing compounds
- •15. Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating Investigator, create a risk for a precipitous decrease in blood pressure.
- •16. Medical history that includes any condition, or requires the use of concomitant medications which, in the Investigator’s judgment, are associated with or create a risk of increased carotid sinus sensitivity, symptomatic bradycardia, or syncopal episodes.
研究者
相似试验
进行中（未招募）
1 期
A Study of Superoxide Dismutase Mimetic GC4419 for the reduction of Severe Oral Mucositis (SOM) in patients with head and neck cancerSevere Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck CancerMedDRA version: 20.0Level: LLTClassification code 10028130Term: Mucositis oralSystem Organ Class: 100000004856EUCTR2019-002745-38-PLGalera Therapeutics, Inc.70
进行中（未招募）
1 期
A Study of Superoxide Dismutase Mimetic GC4419 for the reduction of Severe Oral Mucositis (SOM) in patients with head and neck cancerEUCTR2019-002745-38-CZGalera Therapeutics, Inc.70
进行中（未招募）
1 期
A Study of Superoxide Dismutase Mimetic GC4419 for the reduction of Severe Oral Mucositis (SOM) in patients with head and neck cancerSevere Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck CancerMedDRA version: 20.0Level: LLTClassification code 10028130Term: Mucositis oralSystem Organ Class: 100000004856EUCTR2019-002745-38-ESGalera Therapeutics, Inc.70
进行中（未招募）
不适用
An Open-Label Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene (Histamine Dihydrochloride) Given in Conjunction with Low-Dose Interleukin-2 (IL-2 Proleukin) on Immune Response and Minimal Residual Disease (MRD) in Adult Patients with Acute Myeloid Leukemia in First Complete Remission (CR1) - EPC2008-02 Ceplene and IL-2 in AMPatients affected by Acute Myeloid LeukemiaMedDRA version: 12.1Level: LLTClassification code 10000887Term: Acute myeloid leukemia in remissionEUCTR2009-012083-14-ITEpiCept Corporation150
进行中（未招募）
1 期
An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene® (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin?), on Immune Response and Minimal Residual Disease (MRD) in Adult Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)EUCTR2009-012083-14-FREpiCept Corporation84